Literature DB >> 19930235

Integrated Management of Physician-delivered Alcohol Care for Tuberculosis Patients: Design and Implementation.

Shelly F Greenfield1, Alan Shields, Hilary Smith Connery, Viktoriya Livchits, Sergey A Yanov, Charmaine S Lastimoso, Aivar K Strelis, Sergey P Mishustin, Garrett Fitzmaurice, Trini A Mathew, Sonya Shin.   

Abstract

BACKGROUND: While the integration of alcohol screening, treatment, and referral in primary care and other medical settings in the U.S. and worldwide has been recognized as a key health care priority, it is not routinely done. In spite of the high co-occurrence and excess mortality associated with alcohol use disorders (AUDs) among individuals with tuberculosis (TB), there are no studies evaluating effectiveness of integrating alcohol care into routine treatment for this disorder.
METHODS: We designed and implemented a randomized controlled trial (RCT) to determine the effectiveness of integrating pharmacotherapy and behavioral treatments for AUDs into routine medical care for TB in the Tomsk Oblast Tuberculosis Service (TOTBS) in Tomsk, Russia. Eligible patients are diagnosed with alcohol abuse or dependence, are newly diagnosed with TB, and initiating treatment in the TOTBS with Directly Observed Therapy-Short Course (DOTS) for TB. Utilizing a factorial design, the Integrated Management of Physician-delivered Alcohol Care for Tuberculosis Patients (IMPACT) study randomizes eligible patients who sign informed consent into 1 of 4 study arms: (1) Oral Naltrexone + Brief Behavioral Compliance Enhancement Therapy (BBCET) + treatment as usual (TAU), (2) Brief Counseling Intervention (BCI) + TAU, (3) Naltrexone + BBCET + BCI + TAU, or (4) TAU alone.
RESULTS: Utilizing an iterative, collaborative approach, a multi-disciplinary U.S. and Russian team has implemented a model of alcohol management that is culturally appropriate to the patient and TB physician community in Russia. Implementation to date has achieved the integration of routine alcohol screening into TB care in Tomsk; an ethnographic assessment of knowledge, attitudes, and practices of AUD management among TB physicians in Tomsk; translation and cultural adaptation of the BCI to Russia and the TB setting; and training and certification of TB physicians to deliver oral naltrexone and brief counseling interventions for alcohol abuse and dependence as part of routine TB care. The study is successfully enrolling eligible subjects in the RCT to evaluate the relationship of integrating effective pharmacotherapy and brief behavioral intervention on TB and alcohol outcomes, as well as reduction in HIV risk behaviors.
CONCLUSIONS: The IMPACT study utilizes an innovative approach to adapt 2 effective therapies for treatment of alcohol use disorders to the TB clinical services setting in the Tomsk Oblast, Siberia, Russia, and to train TB physicians to deliver state of the art alcohol pharmacotherapy and behavioral treatments as an integrated part of routine TB care. The proposed treatment strategy could be applied elsewhere in Russia and in other settings where TB control is jeopardized by AUDs. If demonstrated to be effective, this model of integrating alcohol interventions into routine TB care has the potential for expanded applicability to other chronic co-occurring infectious and other medical conditions seen in medical care settings.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19930235      PMCID: PMC2898509          DOI: 10.1111/j.1530-0277.2009.01094.x

Source DB:  PubMed          Journal:  Alcohol Clin Exp Res        ISSN: 0145-6008            Impact factor:   3.455


  101 in total

1.  Estimates of total alcohol consumption in Russia, 1980-1994.

Authors:  A V Nemtsov
Journal:  Drug Alcohol Depend       Date:  2000-02-01       Impact factor: 4.492

2.  A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse.

Authors:  J Chick; R Anton; K Checinski; R Croop; D C Drummond; R Farmer; D Labriola; J Marshall; J Moncrieff; M Y Morgan; T Peters; B Ritson
Journal:  Alcohol Alcohol       Date:  2000 Nov-Dec       Impact factor: 2.826

3.  Psychosocially enhanced treatment for cocaine-dependent mothers: evidence of efficacy.

Authors:  J R Volpicelli; I Markman; J Monterosso; J Filing; C P O'Brien
Journal:  J Subst Abuse Treat       Date:  2000-01

4.  Directly observed therapy and treatment adherence.

Authors:  J Volmink; P Matchaba; P Garner
Journal:  Lancet       Date:  2000-04-15       Impact factor: 79.321

5.  Using naltrexone in inpatient alcoholism treatment.

Authors:  P C Knox; D M Donovan
Journal:  J Psychoactive Drugs       Date:  1999 Oct-Dec

6.  Alcohol and cardiovascular mortality in Moscow; new evidence of a causal association.

Authors:  L Chenet; M McKee; D Leon; V Shkolnikov; S Vassin
Journal:  J Epidemiol Community Health       Date:  1998-12       Impact factor: 3.710

7.  Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial.

Authors:  H R Kranzler; V Modesto-Lowe; J Van Kirk
Journal:  Neuropsychopharmacology       Date:  2000-05       Impact factor: 7.853

8.  Effectiveness of brief interventions to reduce alcohol intake in primary health care populations: a meta-analysis.

Authors:  K Poikolainen
Journal:  Prev Med       Date:  1999-05       Impact factor: 4.018

9.  [Analysis of mortality rates among patients with pulmonary tuberculosis].

Authors:  Kh Kh Zhamborov
Journal:  Probl Tuberk       Date:  1999

10.  Alcohol consumption in a national sample of the Russian population.

Authors:  M Bobak; M McKee; R Rose; M Marmot
Journal:  Addiction       Date:  1999-06       Impact factor: 6.526

View more
  18 in total

1.  Alcoholic Liver Disease in Asia, Europe, and North America.

Authors:  Suthat Liangpunsakul; Paul Haber; Geoffrey W McCaughan
Journal:  Gastroenterology       Date:  2016-02-27       Impact factor: 22.682

2.  Alcohol use and the management of multidrug-resistant tuberculosis in Tomsk, Russian Federation.

Authors:  A C Miller; I Y Gelmanova; S Keshavjee; S Atwood; G Yanova; S Mishustin; J J Furin; S S Shin
Journal:  Int J Tuberc Lung Dis       Date:  2012-04-09       Impact factor: 2.373

3.  Outcomes and follow-up of patients treated for multidrug-resistant tuberculosis in Orel, Russia, 2002-2005.

Authors:  J S Cavanaugh; B Y Kazennyy; M L Nguyen; E V Kiryanova; E Vitek; T M Khorosheva; E Nemtsova; J P Cegielski
Journal:  Int J Tuberc Lung Dis       Date:  2012-06-11       Impact factor: 2.373

4.  Effectiveness of alcohol treatment interventions integrated into routine tuberculosis care in Tomsk, Russia.

Authors:  Sonya Shin; Viktoria Livchits; Hilary Smith Connery; Alan Shields; Sergei Yanov; Galina Yanova; Garrett M Fitzmaurice; Adrianne K Nelson; Shelly F Greenfield
Journal:  Addiction       Date:  2013-05-13       Impact factor: 6.526

5.  Substance Use Disorders in Global Mental Health Delivery: Epidemiology, Treatment Gap, and Implementation of Evidence-Based Treatments.

Authors:  Hilary S Connery; R Kathryn McHugh; Meghan Reilly; Sonya Shin; Shelly F Greenfield
Journal:  Harv Rev Psychiatry       Date:  2020 Sep/Oct       Impact factor: 3.732

6.  Risk factors and timing of default from treatment for non-multidrug-resistant tuberculosis in Moldova.

Authors:  H E Jenkins; A Ciobanu; V Plesca; V Crudu; I Galusca; V Soltan; T Cohen
Journal:  Int J Tuberc Lung Dis       Date:  2013-03       Impact factor: 2.373

7.  Multidrug-resistant tuberculosis in Belarus: the size of the problem and associated risk factors.

Authors:  Alena Skrahina; Henadz Hurevich; Aksana Zalutskaya; Evgeni Sahalchyk; Andrei Astrauko; Sven Hoffner; Valiantsin Rusovich; Andrei Dadu; Pierpaolo de Colombani; Masoud Dara; Wayne van Gemert; Matteo Zignol
Journal:  Bull World Health Organ       Date:  2012-11-26       Impact factor: 9.408

8.  Training and fidelity monitoring of alcohol treatment interventions integrated into routine tuberculosis care in Tomsk, Russia: the IMPACT Effectiveness Trial.

Authors:  Hilary Connery; Shelly Greenfield; Viktoriya Livchits; Lana McGrady; Nickolette Patrick; Charmaine S Lastimoso; Jessica H Heney; Adrianne Katrina Nelson; Alan Shields; Yekaterina P Stepanova; Lidia Y Petrova; Oleg V Anastasov; Olga I Novoseltseva; Sonya S Shin
Journal:  Subst Use Misuse       Date:  2013-06-10       Impact factor: 2.164

9.  Psychiatric morbidity and other factors affecting treatment adherence in pulmonary tuberculosis patients.

Authors:  Argiro Pachi; Dionisios Bratis; Georgios Moussas; Athanasios Tselebis
Journal:  Tuberc Res Treat       Date:  2013-04-15

10.  Does Alcohol consumption during multidrug-resistant tuberculosis treatment affect outcome?. A population-based study in Kerala, India.

Authors:  Karthickeyan Duraisamy; Sunilkumar Mrithyunjayan; Smita Ghosh; Sreenivas Achuthan Nair; Shibu Balakrishnan; Jayasankar Subramoniapillai; John E Oeltmann; Patrick K Moonan; Ajay M V Kumar
Journal:  Ann Am Thorac Soc       Date:  2014-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.